# Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia

> **NCT03520049** · PHASE3 · UNKNOWN · sponsor: **Unity Health Toronto** · enrollment: 30 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Oseltamivir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03520049
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520049, "Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03520049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*